Ophthalmic Ultrasound Imaging Systems Market Size, Share, Growth, Trends and Forecast 2018 – 2026

Ophthalmic ultrasound imaging system is non-invasive visualization technique, which is more convenient and relatively inexpensive as compared to other techniques such as optical coherence tomography (OCT), magnetic resonance imaging (MRI), and scanning Scheimpflug. Ophthalmic ultrasound imaging systems allow imaging of anatomy and pathology involving the anterior and posterior segment of the eye.

This system provides diagnostic information in conditions such as glaucoma, trauma, cysts, and neoplasms. It also allows measurement of length of cornea and other information before conducting procedures such as cataract surgery. There are various types of imaging systems such as A scan (for measurement of axial length), B-scan (for anterior and posterior segment visualization), Pachymeter, and Ultrasound Bio microscope.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1549

Typical instrument use frequency of sound in between 10- 50 MHz, which gives clearer images with higher frequency and lower wavelength. In the ophthalmic ultrasound imaging systems, there is a transducer probe placed in a medium, which generates waves of specific frequency and these waves strikes interior structures in the eye. This waves received by transducer and resulting voltages are then amplified and processed to form images. Depending upon the condition such as angle closure glaucoma, ciliary body cysts, neoplasms, and angle trauma, different types of modalities are used.

Market Dynamics

Increasing prevalence of eye disease such as uncorrected refractive errors, glaucoma, cataract, ciliary body cysts, neoplasms, and angle trauma are major driving factors for growth of the ophthalmic ultrasound imaging systems market. According to 2017 factsheet by World Health Organization (WHO), around 253 million people across the globe suffered from vision impairment and 36 million are blind and 217 million have moderate to severe vision impairment. Chronic eye diseases, which includes uncorrected refractive errors, un-operated cataract, age related macular degeneration, and glaucoma are main causes of vision loss.

This is observed in low- and middle-income countries. According to a study published in the Journal Ophthalmology (2014), around 64.3 million people (aged 40-80 years) in 2013 were affected with glaucoma, which would increase to 76.0 million in 2020 and 111.8 million in 2040. This is expected to aid in growth of the ophthalmic ultrasound imaging systems market. According to population Prospect Report in 2017, the geriatric population (aged 60 years and above) is expected to increase from 900 million in 2017 to 2.1 billion by 2050. Therefore, demand for such imaging products is expected to increase significantly.

Manufacturers are focusing on developing new advanced imaging systems for application in intraocular measurement and anterior segment examination and this is expected to propel growth of the ophthalmic ultrasound imaging systems market. For instance, Quantel Medical, in October 2017, launched next-generation compact touch ophthalmic ultrasound system, which is a 3-in-1 system that combines A scan, B scan, and pachymeter thereby, allows multiple functions.

Regional Dynamics

On the basis of regions, ophthalmic ultrasound imaging systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant in the ophthalmic ultrasound imaging systems market over forecasted period. This is due to better healthcare infrastructure and high spending on healthcare.

Key players operating in the ophthalmic ultrasound imaging systems market are Sonomed Escalon, Quantel Medical, Carl Zeiss Meditech AG, Ellex Medical Lasers Ltd., DGH Technology, Inc NIDEK CO., LTD., MEDA Co., Ltd, Halma plc, Micro Medical Devices, Inc., Optos plc, and Sonogage, Inc.

Click To Read More On Ophthalmic Ultrasound Imaging Systems Market

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2018 Expected Vast Growth By 2026 Including Freelancers, Intake, Trials & Forecast By Application, Technologies

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital Associated MRSA Infection (HA-MRSA) or community-associated MRSA infections (CA-MRSA).

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1538

Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection), osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic bursitis (formation of small fluid-filled sacs under the skin).
Growth of the methicillin-resistant staphylococcus aureus (MRSA) drug market is driven by increasing product pipeline and increasing adoption of organic and inorganic strategies by key market players.

Increasing number of pipeline products for the treatment of methicillin resistance staphylococcus aureus infection is expected to fuel growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market during the forecast period. For instance, in 2014, Cubist Pharmaceuticals Inc., received US FDA approval for its new antibiotic, Sivextro, available in both the forms – injection as well as oral, to treat skin infection caused by gram positive bacteria including MRSA. Moreover, new route of administration are experimented by market players to treat MRSA infection. For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat with post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). These increasing number of product approvals is expected to aid in growth of the MRSA drugs market over the forecast period.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitor

Key market player in methicillin-resistant staphylococcus aureus (MRSA) drugs market are Basilea Pharmaceutica Ltd., Cubist Pharmaceuticals Inc., Melinta Therapeutics, Inc., Theravance Biopharma, Allergan, Merck & Co., Xellia Pharmaceuticals ApS (owned by Novo Holdings A/S), King Pharmaceuticals Inc. (a wholly owned subsidiary of Pfizer), and PF Prism C.V. Players in the market are focusing inorganic growth strategies in order to enhance its market share and remain competitive in the market. For instance, in 2017, Melinta Therapeutics, Inc., acquired the infectious disease business from The Medicines Company. The acquisition includes three marketed products, one of which is Orbactiv, an injectable MRSA drug.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Restraint

Growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market is expected to be hampered by growing bacterial resistance. Further patent expiration of currently existing drugs will lead to large revenue losses to key players due to introduction of low cost generic drugs. Declining patient burden further restrains growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market. According to Centers for Disease Control and Prevention (CDC) studies, hospital associated MRSA infection has declined up to 54% between 2005 and 2011. This can be attributed to increasing awareness for personal and public hygiene.

Moreover, funding programs by healthcare organization will also propel drug discovery and development program, in turn leading to growth of the MRSA drug market. For instance, in 2017, Cystic Fibrosis Foundation Therapeutics (CFFT)—a non-profit drug discovery and development arm of Cystic Fibrosis Foundation—awarded US$ 5 million to Savara Inc., a clinical-stage specialty pharmaceutical company, for the development of AeroVanc, vancomycin hydrochloride inhalation powder, intended to treat MRSA lung infection in individual with cystic fibrosis.

Click To Read More On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

Biomarkers Market Size Growth Rate by Product Forecast 2026

Biomarkers are the molecules used for diagnosis of diseases as these indicate normal or abnormal process in the body. Biomarkers can be any molecules such as DNA (genes), proteins or hormones that indicate about the health and can be classified on basis of different parameters, which includes characteristics such as imaging biomarkers or molecular biomarkers. Demand for biomarkers is increasing in drug discovery and development process, as use of biomarkers increases the success rate in drug development process, decrease costs, and improves patient outcome. Biomarkers also aid in predicting drug efficacy, quickly, than conventional clinical endpoints.

Ask For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1530

Biomarkers are gaining significant traction in product development and treatment of disorders related to chromosome structure, Turner syndrome, Down syndrome, Patau syndrome, Edwards’s syndrome, and others, which is propelling demand for biomarkers. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury, Banyan BTI. Therefore, introduction of such innovative diagnostic tools for various disease indication is projected to fuel growth of the biomarkers market over the forecast period.

Moreover, pharmaceutical companies have started outsourcing the complex bio analysis not only to cut down costs, however, to take advantage of specialized expertise to improve efficiency in drug development process. For instance, in March 2018, the SenzaGen signed a key license agreement with Burlesson Research Technologies, Inc., (BRT)—a contract research organization in the U.S., specializing in immunotoxicology. This agreement, will provide BRTs ‘GARD’ to a broader market. GARD is a group of tests for assessing chemical sensitizers, where the test uses genetic biomarkers for over 200 genes, which cover an entire immune reaction and are relevant to predicting the risk of hypersensitivity. Such advancement and innovation by CROs is expected to favor growth of biomarkers market in the near future.

The biomarkers market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

Increasing application and awareness about biomarker tests is expected to be a major factor for growth of the market. Biomarkers are used for diagnostics and early detection of specific diseases over the conventional diagnostics methods. Furthermore, biomarkers such as BRCA1, indicates whether an individual has an increased likelihood of developing cancer. Biomarkers are also applied to a wide variety of therapeutic areas, which include neurological diseases, metabolic disorders, immune deregulation and oncology to treat various disease such as TMI, cancer, Alzheimer diagnosis. Biomarkers are also used to detect ABO haemolytic disease of new born, Huntington disease, and hereditary haemochromatosis, and cystic fibrosis.

Precision Medicine Initiative have led to development of novel drugs and new treatments, tailored for specific characteristic such as person’s genetic makeup or genetic profile of an individual tumor that helps to transform the way of treatment. This also favors growth of the biomarkers market in the near future. As for the development of precision medicine, it is essential to identify biomarkers.

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc.,  

Click To Read More On Biomarkers Market

Wound Care Biologics Market Competitive Insights , Future Analysis By Key Players

Wound care biologic products facilitates in innate repair mechanisms, and involves the use of active biological agents such as animal and plant-derived active biomolecules, which exhibit antioxidant, antimicrobial, or anti-inflammatory properties. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination. Biologic skin substitute products include tissue-engineered products, which are designed to either temporarily or permanently replace the altered skin. Skin substitutes are commonly used products for wound management and have application for treating various ailments such as pressure ulcers, diabetic neuropathic ulcers, and vascular insufficiency ulcers.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1506

Market Dynamics

Increasing incidences of chronic ulcers, owing to rising prevalence of diabetes, increasing surgical procedures, and rise in trauma cases are major driving factors for growth of wound care biologics market. According to the survey by World Health Organization, 2014, injuries resulting from traffic collisions, drowning, poisoning, falls or burns account for 9% of the global mortality. Also, according to a study by BMJ Journal Injury Prevention, 2013, an estimated 973 million people sustained injuries that warranted some type of healthcare and 4.8 million people died from injuries. The Journal also stated that major injury causes included road injury (29.1%), self-harm (17.6%), falls (11.6%), and interpersonal violence (8.5%). Manufacturers are also focused on extensive research and development to develop new products and expand their product portfolio.

Asia Pacific is expected to exhibit significant growth in the global wound care biologics market over the forecast period. This is owing to high prevalence of diabetic patients in Asian countries. According to the Indian Diabetes Research Foundation, 2016, around 60% of the world’s population suffering from diabetes lives in Asia, with around one-half in China and India combined. The Foundation also states that Western Pacific reported over 138.2 million people suffering from diabetes, the number for which is expected to rise to 201.8 million by 2035.

Chronic wounds have a significant impact on the health and quality of life of patients and their families, causing pain, emotional stress, restriction on daily activities, depression, distress, and anxiety, with prolonged hospital stay and chronic morbidity. According to the Advances in Wound Care Journal, 2015, chronic leg and foot ulcers last for around 12 months on an average, with recurrence affecting up to 65% of patients, leading to loss of function and decreased quality of life. It is also a significant cause of morbidity. Rising incidence of traumatic events such as accidents and fire accidents causing burns, systemic illness, antibiotic resistant, chronic disease, surgery, and impaired mobility are the prevailing factors resulting in increasing incidence of chronic wounds.

Major players operating in the global wound care biologics market are Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amino Technology LLC, and Osiris Therapeutics, Inc.

Click To Read More On Wound Care Biologics Market

Cast Removal Device Market Foresees Skyrocketing Growth in the Coming Years

Cast removal devices are designed to cut cast material such as fiberglass, plastic or plaster and bandage that are used for rehabilitation of the fractured bones or ruptured tendons. It is mainly used by orthopedic surgeons in hospitals and clinics to cure musculoskeletal injuries caused due to road accidents and during sports practices. According to the U.S. Department of Health & Human Services report on January 2018, road traffic injuries are a huge economic burden on low and middle income economies and are estimated to cost US$ 518 billion globally.

Cast Removal Devices Market – Competitors

The major players operating in the cast removal devices market include DeSoutter medical, Erbrich Instrumente GmbH, Ermis MedTech, Hanshin Medical Co.,ltd, HEBUmedical GmbH, Osimed medical, Rimec S.R.L., Shanghai Bojin Medical instrument Co., Ltd., Stryker, and TREU-Instrumente GmbH.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1493

In many areas in the emerging economies, technology has still not found there roots to grow and people use home remedies such as securing with wooden sticks instead of casting plaster. The development of hospital facilities in these areas will drive growth of cast removal device market. In November 2016, Stryker Corporation, one of the world’s leading medical technology company, announced a multi-year collaboration with Indo UK Institute of Health’s (IUIH) Medicity Program to serve greater access to affordable services to patients in India, which will also help in propelling growth of cast removal device market.

The upcoming 2030 Agenda for Sustainable Development adopted by world leaders aims at halving the global number of deaths and injuries from road traffic crashes by 2020. Moreover, from 2015-2019, the World Health Organization is collaborating with the Bloomberg Initiative for Global Road Safety (BIGRS) to reduce fatalities and injuries from road traffic crashes. Such forthcoming schemes of the governmental organizations will hinder growth of cast removal devices market, whereas people neglecting traffic rules or distracted driving because of alcohol and other abuse, unsafe road infrastructure, below mark vehicle quality, and many others factors are expected to propel the cast removal device market growth.

The global cast removal market is regionally segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in cast removal device market due to local manufacturers and high incidence of road injuries.

The strategies adopted by key market players to come up with innovative technologies such as noise free or debris free plaster cutters at affordable rates are lucrative opportunities for growth of the cast removal device market. Cast removal devices are scary and traumatic for most of the patients due to noise and blade rotation, however, OrthoPediatrics’s Quiet cast removal device was a major leap forward in technology in 2009. Shanghai Bojin Medical instrument Co., Ltd. aimed at coming up with products and solutions with reduced medical costs and lessening the financial burden of the patients.

Click To Read More On Cast Removal Device Market

Body Composition Analyzers Market to 2026- Strategies, Applications and Competitive Landscape

The proportion of water, protein, mineral, and fat, in the human body, aids in determining the health of an individual. To measure these, devices such as body composition analyzers are used in fitness centres and hospitals, for weight control. This equipment can be used in screening of certain diseases and conditions related to body weight and composition. Apart from this, it is also used in monitoring and prevention of conditions caused by excessive fat deposits such as diabetes, hyperlipidemia, cholelithiasis, and fatty liver.

Furthermore, it aids in monitoring body composition changes in individuals, and to assess the effectiveness of nutrition and exercise programmers, both for health and physical fitness especially among obese population. According to World Health Organisation (WHO), 2017, the worldwide prevalence of obesity nearly tripled between 1975 and 2016. This increasing prevalence of obesity and increasing government initiatives to create awareness about obesity and its health issues related to obesity are factors expected to propel growth of the market.

Ask For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1485

Body Composition Analyzers Market – Competitors

Key players in the global body composition analyzers market are Omron Corporation, Beurer GmbH, Tanita, InBody Co., Ltd, GE Healthcare, SECA, AccuFitness LLC, and Selvas Healthcare lnc. (Jawon medical Co. Ltd.).

Body Composition Analyzers Market Dynamics

New product launches through increasing R&D activities by key market players is expected to aid in growth of the body composition analyzers market. For example, InBody Co., Ltd. is one of the key players on the market that is engaged in manufacturing body composition analyzers. In October 2017, InBody Co., Ltd. launched band 2, which is fusion of body composition analyzers and fitness trackers. Integration of technologies such as Bluetooth wireless technology, BMI indicator, and past record tracker are expected to aid in increasing adoption of these devices. Furthermore, SELVAS Healthcare launched next generation body composition analyzer, ACCUNIQ BC380 with innovative software technologies and better product design, UI screens and result sheet in comparison to its old models. In addition to this, in 2015, this same company changed its name to Jawon Medical Co., Ltd. through a merger with HEAMS International, and launched two new products named X-SCAN PLUS 970, a body fat analyzer and COZY-930 Candy 5 HD II, a body composition and body water monitoring system.

According to WHO, 2016, 13% of the global population was overweight, which comprises 11% of men and 15% of women. Furthermore, according to OECD’s Obesity Update 2017 report, obesity rates of the U.S. was 38.2% and ranked the first, while Mexico ranked the second with 32.4%. Obese population is more prone to metabolic as well as weight related disorder such as osteoarthritis, heart diseases, diabetes, high blood pressure etc. Overweight and obesity as well as their related diseases are largely preventable. So awareness for weight related health issues and governmental initiatives for healthier life will aid in growth of body composition analyzer market. Increasing prevalence of obesity is one of the major factors fuelling growth of body composition analyzer market. However, high cost of the devices is expected to be a major factor hindering growth of body composition analyzers market.

Body Composition Analyzers Market – Regional Analysis

In terms of geography, the body composition analyzers market is segmented into North America, Europe, Asia Pacific, Middle East, Latin America, and Africa. U.S. is estimated to be dominant market in forecast period due to government initiatives to promote physical activity and advancement in technology. Asia Pacific is expected to be fastest growing body composition analyzer market due to increasing awareness about importance of weight management and fast development in healthcare sector.

Click To Read More On Body Composition Analyzers Market

Over-the-Counter Drugs Market – To Grow in the Coming Years, New Research explores Factors Responsible

The global over-the-counter drugs market is highly competitive, owing to increasing adoption of personal healthcare and self-medication due to rising awareness among the people regarding health precautions and basic drug knowledge. Under such conditions, the competitors experience performance pressure in terms of pricing. Market players are thus focusing on development of OTC drugs in cost-effective way that will help to cater price-sensitive customers, in turn, significantly maintain and subsequently increase profit margins, especially in emerging economies.

The top 10 players operating in the global over-the-counter drugs market include Pfizer, Inc., Novartis AG, GlaxoSmithKline Plc, Bayer AG,,Sanofi, Glenmark Pharmaceuticals, Merck KGaA, Teva Pharmaceuticals, Johnson & Johnson Services, Inc., Boehringer Ingelheim

For More Details Download the PDF brochure: www.coherentmarketinsights.com/insight/request-pdf/1443

Pfizer, Inc. – Pfizer, Inc. is a global leading manufacturer and distributor of over-the-counter drugs, managing its commercial operation through two major business segments namely, Pfizer Innovative Health and Pfizer Essential Health. OTC drugs contribute to a major part of Innovative Health Segment, comprising annual revenue of US$ 29,197 million in 2016.

Novartis AG – Novartis AG, is widely known for its research, development, manufacturing, and marketing of healthcare products across the globe. Novartis operates its drugs business through two major operating channels Innovative Medicine and Drugs manufactured by Sandoz which is a subsidiary of Novartis, has contributed to positioning the company as one of the top players in global Over-the-counter drugs market.

GlaxoSmithKline Plc – GlaxoSmithKline, one of the renowned giant in pharmaceutical industry and over-the-counter drugs market is a global science-led company headquartered in Europe, which develops and manufactures pharmaceutical products, including vaccines, health-related consumer products, and over-the-counter medicines. The consumer healthcare business of GlaxoSmithKline is operated through its subsidiary named GlaxoSmithKline Consumer Healthcare Holdings Ltd. the subsidiary is split into two equal businesses, namely Over-the-counter Medicines and Fast Moving Consumer Goods (FMCG), across four major categories of Oral Health, Wellness, Skin Health, and Nutrition.

Bayer AG – Bayer AG is a global life science company that has a history of over 150 years in areas of healthcare and agriculture. The company operates its business through four major segments namely, Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Over-the-counter drugs contribute to a major revenue share of the consumer health segment, which accounted for US$ 7,179.19 million in 2016.

Sanofi – Sanofi is a global life science company based in France (Europe) that is aimed towards improving healthcare access to people. The company operates its business through two major segments namely, Pharmaceuticals and Vaccines. The company operates its over-the-counter business as a part of a major business segment named Consumer Healthcare (CHC). Sanofi focuses on partnerships and acquisitions to expand its consumer healthcare business.

Following is the Impact Analysis of the strategies employed by the competitors and its impact on the revenues and sales in the global over-the-counter drugs market.

Click To Read More On Over-the-Counter Drugs Market

Gouty Arthritis Market Future Demand Analysis with Forecast 2018 to 2026

Gouty arthritis is characterized by intense joint pain due to deposition of uric acid crystals. Symptoms of gouty arthritis include redness and swelling of joints and intense pain. The condition can be treated with the help of medication. Uric acid is deposited either due to its excess intake or body’s inability to process it leading to inflammation of joint sites such as ankles and toes or wrist. Untreated gouty arthritis may damage joints or kidney as excessive accumulation of uric acid crystals would lead to kidney stone, kidney failure. In most cases, it is observed with other metabolic diseases or conditions such as hypertension, obesity, and diabetes.

Major layers operating in the gouty arthritis market include AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Novartis AG; Savient Pharmaceuticals, GlaxoSmithKline plc, Merck& Co. Inc., Teijin Pharma Ltd., Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, and Nippon Chemiphar Co. Ltd.

Download the  PDF brochure : https://www.coherentmarketinsights.com/insight/request-pdf/1368

New and effective therapies to treat gouty arthritis are expected to fuel growth of gouty arthritis market. For instance, in 2015, Astra Zeneca received FDA approval for novel molecule lesinurad (Zurampic), lesinurad is a urate transport inhibitor which inhibits URAT1, a protein responsible for reabsorption of uric acid in kidneys, given in combination with xanthine oxidase inhibitor helps achieve target serum uric acid level. Asia Pacific region is gaining significant traction in this market, owing to increasing number of patients suffering from chronic diseases such as diabetes and cardiovascular disease or chronic kidney disease, which are rising incrementally as stated by WHO factsheet 2012,this is owing to established fact that around 75% hypertensive patients had gouty arthritis as study published in Journal of Rheumatology in 2014.

High prevalence of associated chronic diseases to provide growth to gouty arthritis market

Other comorbidities such as hypertension is often associated with gout. As per study published in Journal of Rheumatology in 2014, around 75% of gouty arthritis patient were reported to be suffering from hypertension. Therefore patients suffering from chronic disease are at high risk of developing gouty arthritis .High prevalence of gouty arthritis is expected to drive the growth for global gouty arthritis market. According to study published in British Medical Journal in 2017, prevalence of gouty arthritis is 1% to 10% globally. Furthermore, factors such as increasing consumption of high protein food worldwide, linked with gouty arthritis and increasing awareness amongst people for early treatment of disease are​_ the factors boosting growth of gouty arthritis market. However, lack of awareness among the medical fraternity regarding effective treatment of the condition, especially in emerging economies creates a hindrance for gouty arthritis market growth.

For instance, there is different opinion on whether to use urate lowering agents in acute gouty arthritis, urate lowering agent lowers serum urate levels for the dissolution of urate crystals, which is done either by reducing the production of serum uric acid or by promoting its excretion. Moreover, high costs associated with treatment therapy in chronic gouty arthritis hinders the growth of gouty arthritis market.

North America holds dominant position in gouty arthritis market

Regional segmentation of gouty arthritis market by Coherent Market Insights consist of North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate gouty arthritis market, owing high prevalence of gouty arthritis in the U.S. According to Centre for Disease Control and Prevention (CDC), an estimated 54.4 million patients annually suffered from some form of arthritis from 2013 – 2015, in which gouty arthritis carries significant share. According to clinical guidelines for gout published in Annals of Internal Medicine in 2017, about 3.9% of U.S. adults older than 20 years reported about gout at least once in lifetime. Furthermore, increasing geriatric population is driving growth of the market, owing to high prevalence of gouty arthritis in patients above 40 years of age.

Click To Read More On Gouty Arthritis Market

Stem Cell Banking Market Top Manufactures Analysis, Size, Share, Trends and Forecast to 2018-2026

Stem cells are building blocks of the immune system and blood, and they have the ability to develop into other cell types, in order to help in repairing tissues, organs, blood vessels, and are used in treatment of various disease. The ability of stem cells to regenerate has led to development of various treatments with it, to cure various genetic and auto-immune diseases and disorders. Cord blood stem cells have been used to treat nearly 80 diseases, including numerous types of malignancies, anemia, inherited metabolic disorders, and deficiencies of the immune system.

Moreover, with the advancement in regenerative medicine, individuals of all ages can benefit from stem cell therapy in the near future. This is expected to augment growth of the market. Stem cell banking market is expected to gain significant traction, owing to factors such as rising awareness about the therapeutic importance of stem cells, growing number of clinical trials for products that are stem cell-based, and increasing research grants and public-private funding for development of novel treatments that are stem cell-based.

Download the PDF brochure:  https://www.coherentmarketinsights.com/insight/request-pdf/1354

High potential of cord blood and tissues for the treatment of patients with autoimmune diseases is expected to propel the market growth. Moreover, currently available immunosuppressive agents such as steroids, induce long term side effects despite temporary improvements. According to the Health Research Funding, 2015, around 28% of cord blood transplants have been used to treat genetic diseases, with the most common genetic disease treated being severe combined immune deficiency, followed by aplastic anemia.  According to the National Cord Blood Program, 2015, cord blood from unrelated donors has been used as an alternative to bone marrow or mobilized stem cells, as a source of hematopoietic stem cells, with over 35,000 stem cell transplants successfully performed worldwide.

Stem cell banking offers the advantage that it can be readily used, whenever the need for arises, and does not need to be closely matched as bone marrow. According to the Health Research Funding Organization, 2015, children, who received matched cord blood had a 20% higher survival rate than those children who received matched bone marrow. Government organizations are offering support to conduct research and clinical trials for cord blood stem cell. Therefore, healthcare companies are increasing focusing on investing in research and commercialization of cord blood stem cell therapies thus, augmenting growth of stem cell banking market in the near future.

Key features of the study:

This report provides in-depth analysis of stem cell banking market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

Major players operating in the global stem cell banking market are Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.

Click To Read More On Stem Cell Banking Market

Transplant Diagnostics Market To Showcase Energetic Demand During The Period Until 2026

Transplant diagnostics involves assessing compatibility between organ donor and receiver so as to predict any future organ rejection episodes and have contingencies in place. Number of tests are performed such as ABO blood group compatibility, tissue typing, cross matching, panel reactive antibody test, serology screening, and testing for infectious diseases. Increased understanding of the organ rejection phenomenon has led to identification of robust biomarkers along with development of robust biomarker identification tests. Technological advancements in the molecular and non-molecular assays such as PCR, and NGS has increased the data throughput.

Some major players operating in the transplant diagnostics market are Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffman-La Roche Ltd., Immucor, Inc., Becton Dickinson and Company, bioMérieux S.A., Illumina, Inc., CareDx, Inc., and GenDx.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1335

Market Dynamics

Rising prevalence of chronic diseases leading to multiple organ failures; benefits offered by transplant diagnostics, which can predict organ rejection episodes and help in preparing a contingency plan; increasing government initiatives for organ donation awareness; and research and development by leading players to enhance transplant diagnostic products is expected to boost growth of the transplant diagnostics market over the forecast period. For instance, Natera, Inc. and University of California, San Francisco (UCSF), announced a research collaboration in 2016, to study DNA markers of Kidney Transplant Rejection. Furthermore, in 2016, the U.S. government announced plans to invest US$ 200 million to shorten the waiting list of organ transplant patients. These factors are expected to aid in growth of the market over the forecast period.

Advent of new diagnostic tests have improved medical outcomes associated with organ transplants. Organ rejection rate can be minimized by matching the donor and recipient compatibility before transplantation. Conventional techniques in transplant diagnostics include analysis of human leukocyte antigen (HLA). HLA analysis is done in high-throughput laboratories with a limited staff, which is time consuming. However, presence of molecular assay technologies, such as sequencing techniques and PCR-based assays have proved to be efficient. Genetic information can be interpreted on a large scale by using advanced next generation sequencing (NGS) technologies at an affordable price. For instance, Illumina’s MiSeq system offers high-resolution HLA typing and uses next generation sequencing technology, which can be used by any laboratory.

Increasing number of transplantation is expected to increase demand for transplant diagnostics, in order to reduce episodes of organ rejection. Various organizations such as World Health Organization (WHO) and World Health Assembly have implanted action plans such as WHA57.18 to increase awareness regarding transplantation. National Health Service (NHS) Blood & Transplant funded a living transplant initiative in 2016, which was led by the National BAME Transplant Alliance, to increase the number of living transplants from black, Asian, and minority ethnic (BAME) communities.

Click To Read More On Transplant Diagnostics Market